Why 2026 is the Year Momentum Reaches a Critical Mass in the US Biosimilars Market The era of biological competition in America has officially transitioned from a slow start to a high-speed reality this year. In 2026, the US Biosimilars Market is valued at approximately 50.31 billion dollars, representing a massive leap in both clinical adoption and cost-savings. With over 82 FDA approvals to date, biosimilars are no longer seen as experimental alternatives but as the primary...
0 Compartilhamentos
111 Visualizações